This site is intended for healthcare professionals
EMC Drug Feed
Drug information

WindSetlers

OTC
Read time: 1 mins
Last updated: 24 Oct 2018
...
 

Summary of product characteristics


1. Name of the medicinal product

WindSetlers.


2. Qualitative and quantitative composition

Each Capsules contains simeticone 100mg

Also contains sodium ethyl parahydroxybenzoate (E215) and sodium propyl parahydroxybenzoate (E217)

For full list of excipients, see section 6.1


3. Pharmaceutical form

Soft gelatin capsules


4.1. Therapeutic indications

Anti-flatulent defoaming agent for the symptomatic relief of flatulence, wind pains, bloating, abdominal distension and other symptoms associated with intestinal gas


4.2. Posology and method of administration

Oral

Adults, the elderly and children:

One or two capsules taken 3 or 4 times daily or as required for relief


4.3. Contraindications

Hypersensitivity to any of the ingredients.


4.4. Special warnings and precautions for use

None stated.


4.5. Interaction with other medicinal products and other forms of interaction

None reported.


4.6. Fertility, pregnancy and lactation

As dimeticone is not absorbed, it is not anticipated that WindSetlers will have any adverse effects on pregnancy and lactation. However, as with all drugs, caution should be exercised in these conditions.


4.7. Effects on ability to drive and use machines

None stated.


4.8. Undesirable effects

Minor adverse effects: nausea and constipation.

Rarely, hypersensitivity reactions such as rash, pruritis, facial oedema, tongue oedema and respiratory difficulty have been reported.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for 'MHRA Yellow Card' in the Google Play or Apple App Store.


4.9. Overdose

No cases of overdose have been reported. Theoretically, constipation may occur. Treat with fluids and keep under observation.


5.1. Pharmacodynamic properties

WindSetlers contain activated dimeticone, a chemically inert gastric defoaming agent which alters the elasticity of interfaces of mucous-embedded bubbles in the gastro-intestinal tract. The gas bubbles are thus broken or coalesced and in this form, the gas is more easily eliminated through belching or passing flatus.


5.2. Pharmacokinetic properties

Activated dimeticone is not absorbed from the gastrointestinal tract and does not interfere with gastric secretion or absorption of nutrients. Following oral administration, it is excreted unchanged in the faeces.


5.3. Preclinical safety data

None stated.


6.1. List of excipients

Capsule Shell:

Gelatin

Glycerin

Colour (E142)

Quinoline Yellow (E104)

Titanium Dioxide (E171)

Sodium Ethyl Parahydroxybenzoate (E215)

Sodium Propyl Parahydroxybenzoate (E217)

Purified Water


6.2. Incompatibilities

None known.


6.3. Shelf life

Two years unopened.


6.4. Special precautions for storage

Store below 25°C in a dry place.


6.5. Nature and contents of container

25µ cold formed aluminium blister packs in cardboard cartons in packs of 8 and 24 capsules.


6.6. Special precautions for disposal and other handling

Not applicable.


7. Marketing authorisation holder

Thornton & Ross Limited

Linthwaite

Huddersfield

West Yorkshire

HD7 5QH

United Kingdom


8. Marketing authorisation number(s)

PL 00240/0095


9. Date of first authorisation/renewal of the authorisation

1 March 2003


10. Date of revision of the text

10/10/2018

4.1 Therapeutic indications

Anti-flatulent defoaming agent for the symptomatic relief of flatulence, wind pains, bloating, abdominal distension and other symptoms associated with intestinal gas

4.2 Posology and method of administration

Oral

Adults, the elderly and children:

One or two capsules taken 3 or 4 times daily or as required for relief

4.3 Contraindications

Hypersensitivity to any of the ingredients.

4.4 Special warnings and precautions for use

None stated.

4.5 Interaction with other medicinal products and other forms of interaction

None reported.

4.6 Fertility, pregnancy and lactation

As dimeticone is not absorbed, it is not anticipated that WindSetlers will have any adverse effects on pregnancy and lactation. However, as with all drugs, caution should be exercised in these conditions.

4.7 Effects on ability to drive and use machines

None stated.

4.8 Undesirable effects

Minor adverse effects: nausea and constipation.

Rarely, hypersensitivity reactions such as rash, pruritis, facial oedema, tongue oedema and respiratory difficulty have been reported.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for 'MHRA Yellow Card' in the Google Play or Apple App Store.

Drug section

Journals
Journal
Bezlotoxumab for the prevention of Clostridium difficile recurrence.

Introduction:Clostridium difficile infection is a major economic and clinical burden, due to its high frequency of recurrence. Currently recommended treatments are not efficient for prevention...

1 mins
Journal
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.

Background: Clostridium difficile is the most common cause of infectious diarrhea in hospitalized patients. Recurrences are common after antibiotic therapy.

1 min
Journal
Faecal microbiota transplantation: a regulatory hurdle?

During faecal microbiota transplantation, stool from a healthy donor is transplanted to treat a variety of dysbiosis-associated gut diseases. Competent authorities are faced with the challenge to provide adequate regulation.

1 min
CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).